A mechanical circulatory support system for a heart having a cooling element and a method for using the system to treat the effects of a cardiac episode. The support system has a pump comprising a rotor, the rotor having at least one blade. The system also has a catheter having an inner surface and an outer surface, the catheter extending proximally of relative to the pump housing. The outer surface of the catheter is configured to contact blood when disposed within patient vasculature. The outer surface of the catheter comprises a heat transfer surface configured for cooling blood that comes in contact with the outer surface. The support system is operated to provide a temperature selected to cool the circulating blood in contact with the outer surface of the catheter to a temperature selected to reduce or prevent an effect of a cardiac episode.

A mechanical circulatory support system for a heart having a cooling element and a method for using the system to treat the effects of a cardiac episode. The support system has a pump comprising a rotor, the rotor having at least one blade. The system also has a catheter having an inner surface and an outer surface, the catheter extending proximally of relative to the pump housing. The outer surface of the catheter is configured to contact blood when disposed within patient vasculature. The outer surface of the catheter comprises a heat transfer surface configured for cooling blood that comes in contact with the outer surface. The support system is operated to provide a temperature selected to cool the circulating blood in contact with the outer surface of the catheter to a temperature selected to reduce or prevent an effect of a cardiac episode.

Compositions and methods are provided for metabolically degrading ADMA. In one embodiment a device is provided for reducing a patients ADMA levels in their blood wherein the device comprises a biologically active dimethylarginine dimethylaminohydrolase (DDAH) polypeptide covalently linked to a solid support. In one embodiment a method for reducing ADMA levels in a patients blood comprises the step of contacting the patients blood or a blood fraction with an immobilized biologically active DDAH polypeptide, wherein contact of the patients blood with said DDAH polypeptide results in degradation of ADMA present in the patients blood.

Compositions and methods are provided for metabolically degrading ADMA. In one embodiment a device is provided for reducing a patients ADMA levels in their blood wherein the device comprises a biologically active dimethylarginine dimethylaminohydrolase (DDAH) polypeptide covalently linked to a solid support. In one embodiment a method for reducing ADMA levels in a patients blood comprises the step of contacting the patients blood or a blood fraction with an immobilized biologically active DDAH polypeptide, wherein contact of the patients blood with said DDAH polypeptide results in degradation of ADMA present in the patients blood.

This disclosure relates to a catheter system that for precisely positioning fluid flow restrictors within a blood vessel. In particular, this disclosure provides a catheter system that includes a sheath with a first fluid flow restrictor mounted thereto, and a catheter that is slidably disposed within the sheath and has a second fluid flow restrictor mounted thereto. Inside a blood vessel, the sheath and the catheter are separately slidable, thereby allowing the first and second fluid flow restrictors to be positioned at precise locations within the blood vessel.

Cardiac arrest (CA) and traumatic brain injury (TBI) are critical medical events associated with high mortality and long-term disability, primarily due to ischemia and subsequent inflammation. Targeted temperature management (TTM), particularly hypothermia, has proven beneficial in reducing cell death, preserving brain function, and mitigating inflammation following these events. Conventional TTM methods are limited by delayed temperature reduction, poor temperature maintenance, and risks such as thromboembolism. The present invention addresses these challenges by introducing novel devices, apparatus, and systems for extracorporeal whole blood cooling, enabling rapid, controlled induction and maintenance of therapeutic hypothermia. By efficiently cooling the patient's whole blood volume outside the body, the method of the present invention offers a safer, more effective alternative to traditional methods, significantly improving patient outcomes after events such as CA and TBI. The present invention represents a promising advancement in emergency and critical care, enhancing survival and neurological recovery in severely ill patients.

Cardiac arrest (CA) and traumatic brain injury (TBI) are critical medical events associated with high mortality and long-term disability, primarily due to ischemia and subsequent inflammation. Targeted temperature management (TTM), particularly hypothermia, has proven beneficial in reducing cell death, preserving brain function, and mitigating inflammation following these events. Conventional TTM methods are limited by delayed temperature reduction, poor temperature maintenance, and risks such as thromboembolism. The present invention addresses these challenges by introducing novel devices, apparatus, and systems for extracorporeal whole blood cooling, enabling rapid, controlled induction and maintenance of therapeutic hypothermia. By efficiently cooling the patient's whole blood volume outside the body, the method of the present invention offers a safer, more effective alternative to traditional methods, significantly improving patient outcomes after events such as CA and TBI. The present invention represents a promising advancement in emergency and critical care, enhancing survival and neurological recovery in severely ill patients.